The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in patients with type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [4]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294
Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 2
- Toto RD, 2013, J Am Soc Nephrol, 24
- 10.1056/NEJMsr077003 · DOI · Paper page
Cited by
Sorted by citations
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Genetics of diabetes mellitus and diabetes complications
Cole, J. B., & Florez, J. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0278-5 · Cited by 1,797
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy
Jia, G., DeMarco, V. G., & Sowers, J. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.216 · Cited by 976
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
Metadata
- Authors
- Sarafidis, P. A., & Τσάπας, Α.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-17
- Volume
- 374
- Issue
- 11
- Pages
- 1092-1094
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2297835124
- Cited by
- 700
- References
- 9
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 77 · 2023: 91 · 2022: 71 · 2021: 95 · 2020: 93 · 2019: 61 · 2018: 57 · 2017: 62 · 2016: 34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, type 2 diabetes, cardiovascular outcomes, mortality, SGLT2 inhibitors, cardiovascular risk reduction
- MeSH terms
- Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
